Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -66,539 | -22,463 | -16,985 | -11,402 | -6,020 |
| Depreciation Amortization | 11,975 | 8,932 | 5,872 | 2,884 | 10,490 |
| Income taxes - deferred | 33,557 | -5,019 | -2,392 | -336 | -2,886 |
| Accounts receivable | 368 | 6,514 | 7,101 | 6,449 | -5,428 |
| Accounts payable and accrued liabilities | 448 | 1,757 | 1,169 | 410 | 2,582 |
| Other Working Capital | -4,794 | -1,319 | 2,244 | 3,029 | 7,713 |
| Other Operating Activity | 20,299 | 7,683 | 2,974 | -1,159 | 18,928 |
| Operating Cash Flow | $-4,686 | $-3,915 | $-17 | $-125 | $25,379 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 14,056 | 15,059 | -4,517 | 10,270 | -79,062 |
| PPE Investments | -3,832 | -3,026 | -2,370 | -816 | -3,237 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -471 |
| Purchase Sale Intangibles | -106 | -74 | -76 | -2 | -204 |
| Other Investing Activity | -107 | -74 | -74 | -2 | -204 |
| Investing Cash Flow | $10,117 | $11,959 | $-6,961 | $9,452 | $-82,974 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,582 | 4,166 | 2,075 | 690 | 4,181 |
| Debt Repayment | -4,745 | -1,805 | -1,660 | -1,518 | -557 |
| Common Stock Issued | 325 | 240 | 103 | 39 | 1,015 |
| Common Stock Repurchased | -13,925 | -14,405 | -14,434 | -10,627 | -19,907 |
| Other Financing Activity | -669 | -402 | -231 | -129 | -554 |
| Financing Cash Flow | $-13,432 | $-12,206 | $-14,147 | $-11,545 | $-15,822 |
| Exchange Rate Effect | 109 | -1,303 | -2,149 | -1,228 | 4,532 |
| Beginning Cash Position | 98,745 | 98,745 | 98,745 | 98,745 | 167,630 |
| End Cash Position | 90,853 | 93,281 | 75,470 | 95,299 | 98,745 |
| Net Cash Flow | $-7,892 | $-5,465 | $-23,275 | $-3,446 | $-68,885 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,686 | -3,915 | -17 | -125 | 25,379 |
| Capital Expenditure | -4,084 | -3,083 | -2,426 | -849 | -3,525 |
| Free Cash Flow | -8,770 | -6,998 | -2,443 | -974 | 21,854 |